WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 310

Legislative bill overview

HB 310 relates to opioid antagonists in Hawaii but specific provisions are not detailed in the available legislative summary. Based on the bill's subject matter, it likely addresses access to, distribution of, or regulation of medications like naloxone (Narcan) that reverse opioid overdoses. The bill has been referred to Education, Health, and Finance committees, suggesting it may involve funding, healthcare policy, or public health initiatives.

Why is this important

Opioid antagonists are critical emergency medications that can prevent overdose deaths. Policy changes in this area directly affect public health outcomes, emergency response capabilities, and healthcare access during Hawaii's ongoing opioid crisis. Legislative action on these medications can expand harm reduction efforts or establish new regulatory frameworks for their availability.

Potential points of contention

  • Access vs. regulation balance: Tensions between making opioid antagonists widely available (including to non-medical personnel) versus maintaining pharmaceutical oversight and safety protocols
  • Funding mechanisms: Questions about whether taxpayer funding should support free or low-cost distribution programs, particularly in underserved communities
  • Liability protections: Disagreements over "Good Samaritan" protections for individuals who administer antagonists in emergency situations versus accountability measures

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.